TopGum Industries Ltd. closed Q1 2026 with revenues of $31.9 million — up 85.0% year-over-year — and adjusted EBITDA of $5.3 million, a 112.0% surge that pushed margins to 17.0% of revenues. For operators and procurement teams building out functional-food, nutraceutical, or private-label supplement lines, the numbers matter less than the structural move underneath them: TopGum just acquired the gummy manufacturing operations of P&L Developments in the United States, giving the Israeli contract manufacturer its first domestic production footprint in what it describes as its primary target market.
The dietary supplements segment is now carrying the growth story, accounting for roughly 81.0% of total group revenues at $25.8 million — a triple-digit, approximately 162.0% increase over the same quarter last year. More telling for buyers is the order backlog: TopGum reports a record $52 million in confirmed orders covering the next four to five months in dietary supplements alone. Backlogs at that level, sustained across nine consecutive record quarters, indicate demand is structural, not promotional. Competing contract manufacturers in the gummy and soft-chew format space — particularly those serving the US wellness and hospitality retail channel — are operating in the same supply-constrained environment.
The US acquisition accelerates two things operators in the functional-beverage and wellness-retail space should track. First, domestic gummy and chew manufacturing capacity is quietly consolidating around a small number of well-capitalized players with pharma-grade quality systems — which raises the bar for smaller brands trying to secure co-manufacturing slots. Second, TopGum's entry into the pharma sector through the P&L transaction signals that the regulatory ceiling for these formats is rising. Brands positioning supplement-forward SKUs for hotel minibars, spa retail, airline amenities, or C-store adjacency plays will increasingly compete for the same contract slots as OTC pharma accounts. Slot access, minimum order quantities, and lead times are all tightening.
TopGum's own forward guidance frames the opportunity plainly: the company estimates its recent strategic moves could support annual revenues of over $250 million in dietary supplements alone, alongside adjusted EBITDA margins above 20.0%. That projection is not an operator's problem to solve, but it is a signal about where contract manufacturing investment is concentrating. Buyers who have relied on mid-tier co-manufacturers for functional gummy or chew formats should be auditing their supplier relationships now — before capacity allocations shift further toward larger pharma and wellness accounts.
For brand-launch teams and retail buyers inside the hospitality supply chain, the practical read is straightforward: the window to lock in favorable contract manufacturing terms for gummy-format functional products is compressing. Operators building SKUs in this format category should be in active RFP conversations, not watching from the sideline.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.
